Obefazimod in Patients with Moderate-to-Severely Active Ulcerative Colitis: Efficacy and Safety Analysis from the 96-week Open-label Maintenance Phase 2b study.

Fiche publication

Date publication

mai 2025

Journal

Journal of Crohn's & colitis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Vermeire S, Nitcheu J, Gineste P, Flatres A, Santo J, Scherrer D, Peyrin-Biroulet L, Dulai PS, Danese S, Dubinsky M, Tilg H, Siegmund B, Hisamatsu T, Shan K, Rabbat C, Sands BE

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40417999

Résumé

Obefazimod is an oral small molecule that selectively enhances the expression of a single micro-RNA (miRNA), miR-124. Obefazimod has demonstrated safety and efficacy in patients with moderate-to-severely active ulcerative colitis (UC) in a phase 2b induction trial. This analysis presents the two-year outcome data of the open-label maintenance (OLM) study.